However, because the OX40-OX40L-mediated antigen presentation process is also an important pathway in tumor immunity that protects against tumorigenesis [59], the impact of drugs that inhibit OX40-OX40L on tumor development is being carefully examined in terms of long-term safety. The gene discussed is TNFSF4; the disease is neoplasm.